Background: Thrombosis is a major complication and is responsible for cardiovascular diseases (CVDs). The majority of CVDs like stroke, coronary syndrome, and vascular ailments are tightly connected to venous/arterial blood clots. The present research work was planned to address the curative benefits of pinocembrin against thrombosis in the experimental animal model. Materials and methods: The male Wistar rats were employed in this research work and the thrombosis was provoked to the rats via electrical shock by standard method. Animals were treated with 25 and 50 mg/kg of pinocembrin orally. The 20 mg/kg of aspirin was used as a positive control. The level of thrombin-provoked platelet aggregation was performed using the standard method. The plasma coagulation parameters were examined using an automated blood coagulation analyzer. The status of tissue factor pathway inhibitor (TFPI), thromboxane-B2 (TX-B2), 6-keto-PGF1α, and TXB2/6-keto-PGF1α (T/K) was investigated using assay kits. The levels of urokinase-type plasminogen activator (u-PA), tissue-type plasminogen activator (t-PA), PAI-1, and t-PA/PAI-1 were quantified using assay kits. Results: The pinocembrin treatment appreciably prolonged the coagulation parameter time periods like activated partial thromboplastin time, thrombin time, and TP. Pinocembrin also elevated the TFPI, 6-Keto-PGF1α, u-PA, and t-PA status and reduced the platelet aggregation, TX-B2, T/K, PAI-1, and t-PA/PAI-1 levels in the experimental rats. Conclusion: The findings of this work suggested that the pinocembrin exhibited potent antithrombotic activity and it could be a potential candidate to treat the thrombosis in the future.